The Lancet Rheumatology Publishes Clinical Trial Data Demonstrating Promising Safety and Efficacy Profile for a Novel Bioelectronic Device in Patients with Drug Refractory Rheumatoid Arthritis
29 juil. 2020 09h00 HE
|
SetPoint Medical
VALENCIA, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- SetPoint Medical, Inc. today announced that data from a first-in-human pilot trial that evaluated its proprietary Vagus Nerve Stimulation (VNS)...
BioSig Technologies to Participate in LD Micro’s Zooming with LD
23 juil. 2020 08h30 HE
|
BioSig Technologies, Inc.
Westport, CT, July 23, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal...
ViralClear Announces Formation of Its Scientific Advisory Board
20 juil. 2020 13h49 HE
|
BioSig Technologies, Inc.
Westport, CT, July 20, 2020 (GLOBE NEWSWIRE) -- BioSig Subsidiary Enlists Seasoned Professionals in Emerging Infectious Diseases and Regulatory Development to Its Advisory BoardViralClear...
BioSig Technologies to Participate in the B Riley FBR Virtual Infectious Disease Summit
17 juil. 2020 14h42 HE
|
BioSig Technologies, Inc.
Westport, CT, July 17, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal...
BioSig Technologies, Inc. Adopts Stockholder Rights Agreement
16 juil. 2020 17h30 HE
|
BioSig Technologies, Inc.
Westport, CT, July 16, 2020 (GLOBE NEWSWIRE) -- Amended Rights Agreement designed to assure stockholders receive fair and equal treatment in the event of an unsolicited takeoverProvides a guard...
BioSig Technologies, Inc. Adopts Stockholder Rights Agreement
16 juil. 2020 10h30 HE
|
BioSig Technologies, Inc.
Westport, CT, July 16, 2020 (GLOBE NEWSWIRE) -- Rights Agreement designed to assure stockholders receive fair and equal treatment in the event of any proposed takeover Provides a guard against...
Phase II Human Trial of ViralClear's Anti-Viral for SARS-CoV-2 Coronavirus Underway at 4 Key Trial Sites
13 juil. 2020 13h42 HE
|
BioSig Technologies, Inc.
Westport, CT, July 13, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company") and its subsidiary, ViralClear Pharmaceuticals, Inc., today announced the...
BioSig Submits Application to Systems for Award Management (SAM) with U.S. Government
10 juil. 2020 13h15 HE
|
BioSig Technologies, Inc.
Westport, CT, July 10, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing...
ViralClear Pharmaceuticals partners with Albany Molecular Research Inc. on the manufacture of merimepodib active pharmaceutical ingredient development for the potential treatment of COVID-19
08 juil. 2020 13h12 HE
|
BioSig Technologies, Inc.
Westport, CT, July 08, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its subsidiary, ViralClear Pharmaceuticals, Inc., today announced that it is...
BioSig Technologies Inc. Appoints Tony Zook to the Board of Directors
01 juil. 2020 09h15 HE
|
BioSig Technologies, Inc.
Westport, CT, July 01, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal...